DUBLIN, Aug. 17, 2022 /PRNewswire/ -- In response to speculative commentary regarding ranitidine (Zantac®) litigation from a news story that contained certain misleading and inaccurate information, Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today issued the following statement:
Read more at prnewswire.comProvided Content: Content provided by PR Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.